One thing is obvious: 2019 was a good year for enterprise startups raising money at hefty valuations.
The probe is focusing in particular on how trading was handled on the first day the company went public, a report from The Wall Street Journal says.
Top-ranked fund manager Aram Green says this year's disastrous IPO market has produced some good opportunities, and names his three favorites.
"I don't see a happy ending to this," said Vincent Deluard, the director of global macro strategy at INTL FCStone.
These are the top-valued private biotech and healthcare companies in 2019, according to PitchBook.
The company was most recently valued at $500 million in 2018 with its $55 million Series D, which Sapphire Ventures also led.
SV Angel, an early-stage venture firm, has backed 18 businesses that are currently valued at or above $1 billion, making it the single firm with the most unicorn investments.
Mark Cuban says that Uber waited too long to go public.
In this op-ed, Jonathan Shokrian writes that changing the fundamental culture around startup investment will be a monumental, complicated task — but it's necessary.